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Objectives: Interstitial cystitis/bladder pain syndrome (IC/BPS) has debilitating symptoms and results in a
poor quality of life. This study investigated the associations between demographic and clinical factors
and symptom severity in patients with IC/BPS in Taiwan.
Materials and Methods: Patients with documented IC/BPS refractory to conventional treatments from
2007 to 2009 were enrolled. Sociodemographic data and a medical history were obtained. Clinical as-
sessments were performed using the O’LearyeSant IC symptom index (ICSI) and problem index (ICPI),
visual analog scale of bladder pain, and global response assessment to treatment. Patients kept a 3-day
voiding diary of daytime and nighttime frequency, and functional bladder capacity (FBC) and uro-
ﬂowmetry parameters (maximum ﬂow rate, voided volume, and postvoid residual) were measured.
Univariate and multivariate analyses were used to evaluate the associations between demographic/
clinical factors and symptom severity.
Results: A total of 80 patients (75 women and 5 men) were enrolled. On univariate and multivariate
analysis, the characteristics most associated with worse ICSI, ICPI, pain score, daytime frequency and
nocturia episodes, and FBC were maximum bladder capacity (MBC) under anesthesia, duration of
symptoms, body mass index (BMI), and employment status.
Conclusion: MBC and duration of symptoms were predictive factors of symptom severity in patients with
refractory IC/BPS. BMI and employment status were also found to be associated with symptom severity
in these patients.
Copyright  2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic
bladder condition, which includes chronic pelvic pain, pressure, or
discomfort, and is perceived to be related to the urinary bladder in
the absence of urinary infection or other pathology [1,2]. IC/BPS is
seen mainly in women (90%), at a median age of onset of 40 years
[3,4]. The prevalence varies between populations [3,5e8]. Without
a pathognomonic picture, the diagnosis can only be based on a
combination of a thorough patient history, sterile and cytologicallyBuddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
elief Tzu Chi Foundation. Publishenegative urine, cystoscopic hydrodistention under anesthesia, and
bladder biopsy [9].
IC/BPS is one of the most therapeutically frustrating problems of
the urinary tract. Many different etiologies of IC/BPS have been
proposed. However, none of these etiologies has been deﬁnitely
proven. IC/BPS has been considered to result from long-standing
inﬂammation of the bladder. Bladder histological analysis shows
inﬁltrates of mast cells, eosinophilic leukocytes, and T-lympho-
cytes, which suggests the disease is mediated by the immune sys-
tem [10e12]. Disruptions of the bladder mucosal barrier, the
glycosaminoglycan layer, initiate a cascade of events in the bladder,
leading to symptoms and IC/BPS [13,14]. A large range of treatments
have been developed, but no single treatment has been reported to
have long-term effects in eradicating symptoms [15e18].
Patients with IC/BPS have long-term bothersome symptoms
characterized by suprapubic pain, urgency, frequency, and nocturia,
and exacerbated by bladder ﬁlling. Their quality of life is markedlyd by Elsevier Taiwan LLC. All rights reserved.
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risk factors, and impact on quality of life including physical, mental,
sexual, and social function [19e25]. Few studies have focused on
demographic and clinical characteristics that increase symptom
severity. Obesity, depression, a low education level, post-
menopausal status, being unemployed, being unmarried, and never
having been pregnant were associated with worse symptom
severity [26,27]. Volumes at ﬁrst sensation and at maximal cysto-
metric capacity in urodynamic studies were inversely associated
with symptom severity in IC [19,28]. Cystoscopic ﬁndings such as
glomerulations, ulceration, and bladder capacity were signiﬁcantly
correlated with symptoms such as pain and nocturia [22,29]. His-
tological analysis showed the detrusor mast cell count and intra-
fascicular ﬁbrosis had statistically signiﬁcant prognostic value for
treatment intensity [30]. We found no study that demonstrated the
factors associated with IC/BPS in the Taiwanese population.
Symptom severity is strongly related to quality of life. The
treatment of IC/BPS is meant to alleviate symptoms. Identifying
factors associatedwith increased symptom severitymay provide an
insight into the etiology and add potential beneﬁts in the man-
agement of difﬁcult cases. To investigate the association between
demographic/clinical characteristics and symptom severity in pa-
tients with IC/BPS and to determine the predictors of symptom
severity, we carried out a retrospective study in patients with re-
fractory IC/BPS in Taiwan.
2. Materials and methods
Patients who were diagnosed as IC/BPS refractory to conven-
tional treatment at Hualien and Taipei Buddhist Tzu Chi General
Hospitals from 2007 to 2009 were enrolled in this retrospective
study. All patients were over 18 years old and had symptoms
characteristic of IC/BPS. They had been previously treated conser-
vatively with pentosan polysulfate and/or intravesical heparin
instillation for at least 6 months without clinical improvement [31].
Urodynamic study with a 0.4 M potassium chloride (KCl) test was
performed routinely at baseline. All descriptions and terminology
in this report were in accordance with recommendations of the
International Continence Society [1]. The patients received cysto-
scopic hydrodistention under general anesthesia at an intravesical
pressure of 80 cm water and were proven to have characteristic
glomerulations. The grade of glomerulations was classiﬁed as 0 to
4, indicating none, mild, moderate, or severe glomerulations and
patients were also evaluated for the presence of Hunner’s lesion
[32,33]. The maximal bladder capacity (MBC) was recorded. Pa-
tients with a cystometric bladder capacity of more than 350 mL,
without a positive KCl test, or with a glomerulation grade of less
than 2 were not included in this study. Patients with a urinary tract
infection, stress urinary incontinence, chronic urinary retention,
pelvic organ prolapse, or neurogenic voiding dysfunction were also
excluded.
Sociodemographic data including age, sex, body mass index
(BMI), employment status, lifestyle factors such as smoking or
consumption of alcohol, and a medical/reproductive history were
obtained. The history considered comorbidities such as hyperten-
sion, myocardial infarction, irritable bowel syndrome, urinary in-
continence, erectile dysfunction, arthritis, ﬁbromyalgia, migraine
headaches, diabetes, sinusitis, allergies, asthma, endometriosis,
hysterectomy, and nonurogenital cancer.
Our patients were treated with intravesical hyaluronic acid (HA)
instillations 40 mg in 50 mL solution (Cystistat) weekly for 4 weeks
followed by monthly instillation for 5 months [34e37], or intra-
vesical botulinum toxin A (Botox) 100 U injections as previously
described [38e42]. Patients were informed of the possible com-
plications associated with intravesical HA instillation, such asurinary tract infection. Written informed consent was obtained
from every patient prior to participating in the present study.
Clinical assessments performed at baseline, 1 month, and 6
months after treatment start included IC/BPS symptoms, a 3-day
voiding diary, and uroﬂowmetry. The IC/BPS symptoms were
assessed using the O’LearyeSant IC index, which is composed of
two subscales that measure the frequency of IC/BPS symptoms (IC
symptom index, ICSI; range 0e20) and the degree of bother asso-
ciated with symptoms (IC problem index, ICPI; range 0e16) [43,44].
Bladder pain was assessed by a visual analog scale (VAS), ranging
from 0 (no pain) to 10 (severe pain). The patients kept a 3-day
voiding diary to record the functional bladder capacity (FBC),
number of urinary daytime voidings, and nocturia episodes. Uro-
ﬂowmetry and the postvoid residual volume measurement were
also carried out at each time point. A self-assessed global response
assessment (GRA) was used to rate bladder symptoms compared
with baseline on a seven-point centered scale.
Continuous variables were expressed as mean  standard de-
viation (SD), and categorical data were expressed as number and
percentages. Statistical comparisons between the subgroups were
tested using the Chi-square test for categorical variables, and the
independent t test for continuous variables. The paired t test was
used to evaluate signiﬁcant differences in the variables at baseline
and after treatment. All statistical assessments were two-sided and
considered signiﬁcant at p < 0.05.
Because the outcomes of interest indicative of symptom severity
of IC/BPS were in a repeated measurement manner, we used the
generalized estimating equations (GEE) model to assess the asso-
ciation between them and demographics and clinical factors. The
dependent variables including the ICSI, ICPI, pain score, frequency
and nocturia episodes, and FBCmeasured at three time points were
considered the repeated effect. The independent variables were
demographics and clinical factors and were considered the ﬁxed
effect. The correlation structure was unstructured after ﬁtness
testing. Univariate and multivariate analyses were performed.
Based on distribution of case volume, we stratiﬁed age, BMI, MBC,
symptom duration, and number of children into tertiles. The esti-
mate was exponentiated in the form of b. Covariates that retained
p < 0.15 on univariate analysis or had a trend toward a worse
outcome were entered into the multivariate regression models.
Therewere similarities between our dependent variables (ICSI, ICPI,
pain score, frequency, nocturia episodes, and FBC). There might
have been collinearity between these variables. Therefore, an in-
dividual regressionmodel was applied for each dependent variable.
All statistical tests were two-sided and used a signiﬁcance level of
5%. All statistical tests were performed using SAS for Windows,
version 9.1 (SAS Institute Inc., Cary, NC, USA).
3. Results
A total of 80 patients including 75 women and 5 men were
enrolled in this study. Their demographic characteristics and baseline
data, such as symptom duration, daytime frequency and nocturia
episodes, FBC, MBC, ICSI, ICPI, and VAS pain scores, are shown in
Table 1. Fifty six patients received intravesical HA instillation and 24
patients received intravesical Botox injections. There were no signif-
icant differences in the demographic characteristics between the two
treatmentgroups. All patientshadmoderate to severe glomerulations
in cystoscopic hydrodistention, but none had a Hunner’s ulcer.
3.1. Univariate analysis
On univariate analysis ﬁtted by a GEE model, we found that the
independent variables associated with outcome parameters indic-
ative of symptom severity were MBC, duration of symptoms, BMI,
Table 1
Demographic and baseline characteristics of the study participants.
Total HA group Botox group p
Patient number 80 56 24
Age (y) 49.5  13.0 48.6  13.8 51.6  11.0 0.35
Female sex 75 (93.8) 52 (92.9) 23 (95.8) 0.61
BMI (kg/m2) 23.4  3.99 23.81  4.31 22.38  2.95 0.09
Comorbiditya 27 (33.8) 20 (35.7) 7 (29.2) 0.57
Marriage 49.5  13.0 49 (87.5) 22 (91.7) 0.59
Children 69 (86.3) 47 (83.9) 22 (91.7.2) 0.36
Smoking 2 (2.5) 2 (3.6) 0 0.35
Alcohol 2 (2.5) 2 (3.6) 0 0.35
Employment 34 (42.5) 23 (41.1) 11 (45.8) 0.69
Symptom
duration (y)
6.49  5.03 6.22  5.06 7.13  5.02 0.46
MBC (mL) 664  205 657.9  210.3 679.6  194.9 0.67
Frequency 10.8  5.19 11.68  5.82 8.63  2.2 0.001
Nocturia 3.6  1.67 3.11  1.72 2.96  1.57 0.72
FBC (mL) 162.8  91.9 146.4  82.4 200.8  103.0 0.01
IC index (total) 20.7  760 21.39  6.83 19.0  9.09 0.20
ICSI 10.8  3.99 11.11  3.71 10.13  4.59 0.32
ICPI 9.86  3.90 10.29  3.47 8.88  4.69 0.14
VAS score 4.41  2.25 4.34  2.0 4.58  2.8 0.66
Data are shown as mean SD or n (%); p values indicate differences between groups
based on Chi-square test or independent t test.
BMI ¼ body mass index; Botox ¼ botulinum toxin A; FBC ¼ functional bladder ca-
pacity; HA ¼ hyaluronic acid; IC ¼ interstitial cystitis; ICPI ¼ O’LearyeSant IC
problem index; ICSI ¼ O’LearyeSant IC symptom index; MBC ¼ maximum bladder
capacity; SD ¼ standard deviation; VAS ¼ visual analog scale.
a Comorbidity: as described in the text.
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with a worse ICPI, more daytime frequency and nocturia episodes,
and a smaller FBC. An MBC less than 500 mL was associated with a
worse ICSI. A shorter symptom duration was signiﬁcantly associ-
ated with a worse ICSI and ICPI, and more daytime frequency. A
lower BMI was signiﬁcantly associated with a worse ICSI and ICPI,
higher pain score, and more daytime frequency and nocturia epi-
sodes. Unemployment was signiﬁcantly associated with a worse
ICSI, more frequency and nocturia, and a smaller FBC (Table 2).
These four covariates were entered into multivariate analysis.3.2. Multivariate analysis
We anticipated that MBC and symptom duration would reﬂect
the severity of disease, whereas BMI and employment status might
show the impact of disease severity. Thus, we considered MBC and
symptom duration as the main covariates, and BMI and employ-
ment status as confounders on multivariate analysis. Three
regression models were applied by GEE (Table 3).
Model 1 included MBC and symptom duration. A smaller MBC
was signiﬁcantly associated with a worse ICPI, more daytime fre-
quency and nocturia, and a smaller FBC. A shorter duration of
symptoms was associated with a worse ICSI and ICPI, and more
daytime frequency.
Model 2 was adjusted for age, sex, and treatment group, which
were considered a priori factors. A smaller MBC was signiﬁcantly
associatedwith aworse ICPI, more daytime frequency and nocturia,
and a smaller FBC. A shorter symptom durationwas associated with
a worse ICSI and ICPI, and more daytime frequency.
Model 3 was adjusted for age, sex, treatment group, BMI, and
employment status. A smaller MBC was signiﬁcantly associated
with a worse ICPI, more daytime frequency and nocturia, and a
smaller FBC. A shorter duration of symptoms was signiﬁcantly
associated with a worse ICSI and ICPI and more daytime frequency.
In addition, a lower BMI was found to be signiﬁcantly associated
with a worse ICSI and more nocturia episodes, and was associated
with a worse ICPI, higher pain score, and more daytime frequency.Unemployment was signiﬁcantly associated with more daytime
frequency.
Multivariate analyses were also performed for ICSI, ICPI, and
GRA in three regression models ﬁtted by GEE when these outcome
parameters were considered binary variables. ICSI and ICPI scores
of 12 indicated severe IC symptoms, and a GRA  2 indicated a
successful treatment result. A smaller MBC was signiﬁcantly asso-
ciated with a worse ICPI. A shorter duration of symptoms was
associated with a worse ICSI. There were no signiﬁcant associations
between covariates and treatment results based on GRA (Table 4).
4. Discussion
This current study revealed that MBC on cystoscopic hydro-
distention and symptom duration had signiﬁcant associations with
symptom severity in IC/BPS. In addition, BMI and employment
status were observed to have signiﬁcant associations with symp-
tom severity in these patients. There were no deﬁnite interactions
between MBC, symptom duration, and treatment arms in symptom
severity and therapeutic effect.
The main ﬁnding of our study was that the MBC was inversely
correlated with symptom severity in our patients. A smaller MBC,
especially in patients with an MBC less than 500 mL, was signiﬁ-
cantly associated with a worse ICPI, more daytime frequency and
nocturia, and a smaller FBC, suggesting that a small MBC is indic-
ative of severe symptoms. This result was consistent with an
Interstitial Cystitis Data Base study by Kirkemo et al [28] who re-
ported that daytime and nighttime frequency were correlated with
a decreased volume at ﬁrst sensation to void and a lower maximal
cystometric capacity. We believe that bladder capacity under
anesthesia reﬂects the severity of the disease itself, and thus, a
smaller MBC indicates a more severe IC/BPS. Lamale et al [29]
demonstrated that pain and nocturia were signiﬁcantly correlated
with the cystoscopic ﬁndings and bladder capacity in patients with
newly diagnosed IC. All of our patients had moderate to severe
glomerulations and none had a Hunner’s ulcer. However, we did
not assess the association between cystoscopic ﬁndings and
symptom severity.
Another result of our study is that a shorter symptom duration
was signiﬁcantly associatedwith aworse ICSI, and correlatedwith a
worse ICPI and more daytime frequency, suggesting that a short
symptom duration is indicative of severe symptoms. This ﬁnding is
in contrast to that of Koziol et al [22] who found an apparent
plateau in frequency and urgency among patients after approxi-
mately 5 years of symptoms. IC/BPS is a chronic disease, and most
patients have bothersome symptoms occurring in a pattern of ﬂare
and remission [3]. No current treatments have a signiﬁcant impact
on symptoms with time [45]. Patients with a long disease duration
may adjust themselves psychologically or socially across time. In
addition, patients might experience milder symptoms with the
effects of previous treatments. Those with shorter disease duration
may perceive that their symptoms are severe. We did not assess
psychological factors among our patients, and it was not possible to
draw a conclusion.
We observed that BMI was independently associated with IC/
BPS symptom severity. A lower BMI was signiﬁcantly associated
with a worse ICSI and more nocturia episodes, and correlated with
a worse ICPI, more pain, and more daytime frequency. The rela-
tionship between symptoms and body weight in IC/BPS is not well
deﬁned in the literature. El Khoudary et al [27] reported that
obesity was associated with one quality of life domain. The reason
may be due to the chronic nature of IC/BPS and the impaired quality
of life and psychological function in these patients. Our patients
were generalized as thin, with BMIs of about 22e23 kg/m2. We did
not assess the BMI of patients prior to the onset of IC, and it was
Table 2
Univariate analysis for IC/BPS symptoms severity by study covariates.a
Variable
(number of patients)
ICSI ICPI Pain Frequency Nocturia FBC
b p b p b p b P b p b p
Treatment
HA (56) 0.18 0.80 0.55 0.50 0.44 0.31 1.65 0.002 0.34 0.22 37.0 0.07
Botox + HA (24) Ref. Ref. Ref. Ref. Ref. Ref.
Age (y)
<41 (22) 0.08 0.92 0.64 0.42 0.89 0.07 0.63 0.50 0.49 0.16 23.5 0.33
4155 (32) 0.83 0.26 0.62 0.44 0.26 0.54 0.52 0.47 0.80 0.005 12.3 0.55
>55 (26) Ref. Ref. Ref. Ref. Ref. Ref.
p for trend 0.98 0.47 0.08 0.54 0.13 0.33
Sex
Female (75) 0.26 0.87 0.57 0.67 0.68 0.31 1.09 0.26 0.82 0.19 22.9 0.49
Male (5) Ref. Ref. Ref. Ref. Ref. Ref.
BMI (kg/m2)
<20 (13) 1.76 0.05 1.54 0.17 1.08 0.08 1.33 0.24 0.52 0.15 19.5 0.41
20e25 (45) 0.81 0.24 0.48 0.53 0.22 0.61 0.09 0.91 0.37 0.17 17.1 0.36
>25 (22) Ref. Ref. Ref. Ref. Ref. Ref.
p for trend 0.05 0.18 0.10 0.29 0.11 0.61
Comorbidity
No (53) 1.20 0.09 1.41 0.05 0.60 0.14 0.56 0.41 0.26 0.41 35.5 0.04
Yes (27) Ref. Ref. Ref. Ref. Ref. Ref.
MBC (mL)
<500 (12) 1.10 0.14 2.02 0.02 0.66 0.29 3.09 0.002 1.26 0.005 124.1 <0.001
500e800 (39) 0.16 0.83 0.10 0.89 0.90 0.03 0.63 0.30 0.51 0.06 61.5 <0.001
>800 (29) Ref. Ref. Ref. Ref. Ref. Ref.
p for trend 0.33 0.08 0.13 0.003 0.004 <0.001
Duration (y)
<3 (20) 1.46 0.09 1.53 0.09 0.28 0.58 1.42 0.11 0.44 0.27 10.2 0.66
3e7 (32) 1.06 0.145 0.85 0.29 0.19 0.66 0.10 0.88 0.59 0.02 19.3 0.35
>7 (28) Ref. Ref. Ref. Ref. Ref. Ref.
p for trend 0.08 0.09 0.57 0.12 0.21 0.77
Marriage
No (9) 1.20 0.29 1.57 0.20 1.08 0.18 0.05 0.95 0.18 0.66 1.37 0.96
Yes (71) Ref. Ref. Ref. Ref. Ref. Ref.
Number of children
0 (11) 0.25 0.80 0.68 0.53 0.48 0.51 0.06 0.94 0.24 0.54 6.7 0.83
1e2 (43) 1.0 0.11 1.07 0.12 0.53 0.17 0.09 0.91 0.53 0.07 2.1 0.92
>2 (26) Ref. Ref. Ref. Ref. Ref. Ref.
p for trend 0.77 0.99 0.86 1.00 0.28 0.89
Work
No (46) 0.92 0.14 0.38 0.58 0.01 0.98 1.48 0.01 0.40 0.12 28.2 0.10
Yes (34) Ref. Ref. Ref. Ref. Ref. Ref.
Smoking
No (78) 3.61 0.009 3.08 0.13 0.32 0.90 0.81 0.53 1.42 <0.001 33.4 0.002
Yes (2) Ref. Ref. Ref. Ref. Ref. Ref.
BMI ¼ body mass index; Botox ¼ botulinum toxin A; FBC ¼ functional bladder capacity; GEE ¼ generalized estimating equation; HA ¼ hyaluronic acid; IC/BPS ¼ interstitial
cystitis/bladder pain syndrome; ICPI ¼ O’LearyeSant IC problem index; ICSI ¼ O’LearyeSant IC symptom index; MBC ¼ maximal bladder capacity; Ref. ¼ reference.
a Models were ﬁtted by GEE.
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more severe symptoms or if it was a preexisting condition.
We also found that unemployment was signiﬁcantly associated
with more daytime frequency, consistent with the study of El
Khoudary et al [27] who reported a signiﬁcant association between
employment status and physical functioning in IC patients. This
result may be due to the ‘‘healthy worker effect’’ reported in
research on other diseases. That is, healthier and better functioning
individuals are employed. However, whether IC patients who are
employed experience fewer symptoms or whether increased
symptoms are related to not being currently employed is a difﬁcult
relationship to determine in a short-term study. A long-term pro-
spective study is necessary to conﬁrm this observation.
It is notable thatMBC, symptom duration, BMI, and employment
status were not correlated with the severity of bladder/pelvic pain,
characteristics of IC/BPS, in our patients. One explanation is that all
of our participants had previously been treated for IC/BPS. Patients
may experience less pain if they have had analgesics or anti-
inﬂammatory therapy, regardless of the organic or nonorganic
origin of the disease. Treatments may affect pain more than thecystoscopic ﬁndings. Another reason could be confusion about the
deﬁnition of pain. A study of Sirinian et al [46] showed that tandem
pain questions on the ICSI and ICPI did not correlate as highly as
might be expected.
This study is the ﬁrst to comprehensively assess the socio-
demographic and clinical factors that affect the symptom severity
of patients with IC/BPS in Taiwan. After adjusting for important
covariates and using validated instruments, we demonstrated sig-
niﬁcant associations between theMBC and disease duration and IC/
BPS symptom severity. In previous research, IC/BPS symptomswere
studied in a cross-sectional manner. The symptoms of IC/BPS are
not constant with time. Variation in symptoms may not reﬂect the
typical symptoms experienced by patients and could result in
changes in predictors of symptom severity. Given the repeated
measurements of outcome parameters, we believe that the asso-
ciations found in this study are likely to be representative of
symptoms experienced by patients with IC/BPS, rather than sta-
tistical anomalies.
The main limitation of our study was the relatively small sample
size. Our study participants were restricted to patients with IC/BPS
Table 3
Multivariate analysis for IC/BPS symptoms severity by MBC and symptom duration.a
ICSI ICPI Pain
b 95% CI p b 95% CI p b 95% CI p
Model 1
MBC (mL)
<500 1.10 0.45e2.64 0.16 2.01 0.34e3.68 0.02 0.67 1.92e0.58 0.29
500e800 0.25 1.74e1.24 0.74 0.01 1.47e1.45 0.99 0.95 1.75e0.15 0.02
> 800 Ref. Ref. Ref.
p for trend 0.37 0.08 0.13
Duration (y)
<3 1.51 0.15e3.17 0.07 1.59 0.05e3.22 0.06 0.41 0.50e1.32 0.38
3e7 1.12 0.32e2.56 0.13 0.96 0.60e2.53 0.23 0.14 0.72e1.00 0.75
>7 Ref. Ref. Ref.
p for trend 0.07 0.06 0.40
Model 2
MBC (mL)
<500 1.14 0.54e2.82 0.18 2.45 0.76e4.15 0.005 0.19 1.48e1.11 0.78
500e800 0.20 1.66e1.26 0.79 0.08 1.36e1.52 0.91 0.83 1.53e0.12 0.02
>800 Ref. Ref. Ref.
p for trend 0.42 0.05 0.33
Duration (y)
<3 1.41 0.30e3.11 0.11 1.25 0.48e2.99 0.16 0.21 0.79e1.22 0.67
3e7 0.94 0.61e2.48 0.24 0.74 0.91e2.39 0.38 0.23 0.59e1.06 0.58
>7 Ref. Ref. Ref.
p for trend 0.10 0.16 0.64
Model 3
MBC (mL)
<500 0.86 0.75e2.46 0.29 2.29 0.52e4.06 0.01 0.31 1.62e1.00 0.64
500e800 0.12 1.54e1.30 0.87 0.06 1.34e1.46 0.93 0.85 1.55e0.15 0.02
>800 Ref. Ref. Ref.
p for trend 0.50 0.07 0.26
Duration (y)
<3 1.53 0.072.99 0.04 1.38 0.25e3.01 0.10 0.31 0.61e1.23 0.51
3e7 1.00 0.50e2.50 0.19 0.69 0.94e2.31 0.41 0.23 0.58e1.04 0.58
>7 Ref. Ref. Ref.
p for trend 0.04 0.10 0.49
Frequency Nocturia FBC
b 95% CI p b 95% CI p b 95% CI p
Model 1
MBC (mL)
<500 3.00 0.87e5.13 0.006 1.35 0.49e2.21 0.002 121.9 161.2e82.5 <0.001
500e800 0.45 0.63e1.54 0.41 0.52 0.04e1.08 0.07 59.5 93.8e25.1 <0.001
>800 Ref. Ref. Ref.
p for trend 0.008 0.002 <0.001
Duration (y)
<3 1.43 0.24e3.10 0.09 0.41 0.30e1.11 0.26 5.3 42.0e31.5 0.78
3e7 0.28 0.93e1.49 0.65 0.69 0.18e1.20 0.008 11.8 23.9e47.5 0.52
>7 Ref. Ref. Ref.
p for trend 0.10 0.19 0.87
Model 2
MBC (mL)
<500 3.38 1.26e5.49 0.002 1.38 0.54e2.21 0.001 120.5 163.7e77.3 <0.001
500e800 0.50 0.66e1.66 0.40 0.54 0.04e1.11 0.07 56.4 88.9e23.9 <0.001
>800 Ref. Ref. Ref.
p for trend 0.005 0.001 <0.001
Duration (y)
<3 1.03 0.41e2.47 0.16 0.40 0.29e1.09 0.26 3.1 37.7e31.5 0.86
3e7 0.02 1.24e1.19 0.97 0.46 0.04e0.95 0.07 16.0 23.7e55.7 0.43
>7 Ref. Ref. Ref.
p for trend 0.18 0.20 0.98
Model 3
MBC (mL)
<500 3.08 1.27e4.90 0.001 1.33 0.54e2.12 0.001 114.7 157.6e71.7 <0.001
500e800 0.67 0.56e1.90 0.28 0.58 0.02e1.17 0.057 55.0 88.3e21.8 0.001
>800 Ref. Ref. Ref.
p for trend 0.002 0.001 <0.001
Duration (y)
<3 1.18 0.10e2.45 0.07 0.43 0.22e1.08 0.20 7.3 41.9e27.4 0.68
3e7 0.12 0.94e1.18 0.83 0.47 0.02e0.96 0.06 16.7 21.1e54.4 0.39
>7 Ref. Ref. Ref.
p for trend 0.08 0.15 0.84
BMI ¼ body mass index; CI ¼ conﬁdence interval; FBC ¼ functional bladder capacity; GEE ¼ generalized estimating equation; IC/BPS ¼ interstitial cystitis/bladder pain
syndrome; ICPI ¼ O’LearyeSant IC problem index; ICSI ¼ O’LearyeSant IC symptom index; MBC ¼ maximal bladder capacity; Ref. ¼ reference.
a Models were ﬁtted by GEE. Model 1: included MBC and duration; Model 2: adjusted for age, sex, and treatment; Model 3: adjusted for age, sex, treatment, BMI, and work.
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Table 4
Multivariate analysis for ICSI, ICPI, and GRA by MBC and symptom duration.a
ICSI ICPI GRA
OR 95% CI p OR 95% CI p OR 95% CI p
Model 1
MBC (mL)
<500 0.72 1.33e0.67 0.52 3.55 0.18e2.36 0.02 0.74 1.68e1.08 0.67
500e800 0.72 1.22e0.57 0.48 1.15 0.79e1.07 0.76 1.06 0.82e0.94 0.89
>800 Ref. Ref. Ref.
p for trend 0.47 0.06 0.74
Duration (y)
<3 2.17 0.29e1.84 0.15 1.50 0.63e1.45 0.44 0.78 1.35e0.86 0.67
3e7 1.34 0.66e1.25 0.55 1.17 0.76e1.09 0.73 2.57 0.01e1.88 0.05
>7 Ref. Ref. Ref.
p for trend 0.16 0.45 0.90
Model 2
MBC (mL)
<500 0.55 1.65e0.45 0.26 4.30 0.31e2.60 0.01 0.59 1.98e0.94 0.49
500e800 0.76 1.18e0.63 0.56 1.18 0.78e1.10 0.73 1.12 0.82e1.05 0.81
>800 Ref. Ref. Ref.
p for trend 0.30 0.06 0.66
Duration (y)
<3 2.14 0.38e1.90 0.19 1.38 0.83e1.47 0.58 0.79 1.41e0.93 0.69
3e7 1.08 0.99e1.14 0.89 0.96 1.00e0.92 0.93 2.37 0.09e1.82 0.08
>7 Ref. Ref. Ref.
p for trend 0.23 0.62 0.89
Model 3
MBC (mL)
<500 0.46 1.86e0.32 0.17 4.12 0.21e2.62 0.02 0.65 1.90e1.05 0.57
500e800 0.77 1.17e0.64 0.56 1.11 0.85e1.07 0.83 1.11 0.84e1.05 0.83
>800 Ref. Ref. Ref.
p for trend 0.21 0.08 0.72
Duration (y)
<3 2.30 0.20e1.86 0.11 1.41 0.79e1.47 0.55 0.74 1.50e0.90 0.62
3e7 1.09 0.99e1.16 0.87 0.90 0.10e0.89 0.84 2.41 0.07e1.83 0.07
>7 Ref. Ref. Ref.
p for trend 0.16 0.60 0.84
BMI ¼ body mass index; CI ¼ conﬁdence interval; FBC ¼ functional bladder capacity; GEE ¼ generalized estimating equation; GRA ¼ global response assessment; IC/
BPS ¼ interstitial cystitis/bladder pain syndrome; ICPI ¼ O’LearyeSant IC problem index; ICSI ¼ O’LearyeSant IC symptom index; OR ¼ odds ratio; MBC ¼ maximal bladder
capacity; Ref. ¼ reference.
a Models were ﬁtted by GEE, outcome parameters as binary variables, severe symptom deﬁned as ICSI  12, ICPI  12, successful result deﬁned as GRA  2; Model 1:
included MBC and duration; Model 2: adjusted for age, sex, and treatment; Model 3: adjusted for age, sex, treatment, BMI, and work.
C.-H. Peng, H.-C. Kuo / Tzu Chi Medical Journal 26 (2014) 79e8584refractory to conventional treatments. The results may not be
generalized to mild cases, although one can argue that mild cases
would not be bad enough to prompt patients to seek care or to
show improvement results. The study follow-up was short. Our
outcome measures may not necessarily correlate with long-term
results after treatment. Also, the lack of an objective assessment
for urgency and an evaluation of the impact on quality of life may
have subjected our data to omitted variable bias. Further large-scale
and long-time follow-up studies are needed to minimize bias.
In conclusion, our current study showed that MBC and symptom
duration signiﬁcantly correlated with symptom severity in patients
with refractory IC/BPS in Taiwan, indicative of possible predictive
factors. BMI and employment status were independently associ-
ated with symptom severity in these patients.References
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